- Patients with treatment-resistant depression receiving esketamine with SNRI had lower risks of death, hospitalizations, and relapse compared to SSRI.
- Both groups had low rates of mortality, hospitalizations, depression relapses, and suicide attempts.
- Esketamine plus SNRI group showed statistically significant higher 5-year survival rates.
- Importance of choosing the appropriate antidepressant partner for esketamine was emphasized.
- The study used real-world data from the TriNetX health research network and included over 55,000 adults with treatment-resistant depression.
Source: JAMA Psychiatry
